Composition for inducing proliferation or accumulation of regulatory T cells

Patent metadata

Field	Value
Publication number	US-9662381-B2
Application number	US-201615374693-A
Country	US
Kind code	B2
Filing date	Dec 9, 2016
Priority date	Jun 4, 2010
Publication date	May 30, 2017
Grant date	May 30, 2017

Abstract

It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

First claim

The invention claimed is:

1. A method of treating a human subject having an infectious disease, an autoimmune disease or an allergic disease, the method comprising administering to the subject a pharmaceutical composition comprising a spore-forming fraction of human fecal matter, wherein the composition induces proliferation and/or accumulation of regulatory T cells, and wherein the composition is formulated for oral administration.

2. The method of claim 1 , wherein the composition does not include Bacteroides.

3. The method of claim 1 , wherein the composition further comprises a pharmacologically acceptable carrier.

4. The method of claim 1 , wherein the composition is in the form of a capsule.

5. The method of claim 1 , wherein the composition is formulated for delivery to the intestine.

6. The method of claim 1 , wherein the composition is formulated for delivery to the colon.

7. The method of claim 1 , wherein the composition further comprises a pH sensitive composition comprising one or more enteric polymers.

8. The method of claim 1 , wherein the human subject has an autoimmune disease.

9. The method of claim 8 , wherein the autoimmune disease is organ transplant rejection, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, sprue, rheumatoid arthritis, Type 1 diabetes, graft versus host disease, or multiple sclerosis.

10. The method of claim 1 , wherein the subject has an infectious disease.

11. The method of claim 10 , wherein the infectious disease is Clostridium difficile infection.

12. The method of claim 1 , wherein the subject has an allergic disease.

Assignees

• Univ Tokyo

Inventors

• Honda Kenya
• Atarashi Koji
• Itoh Kikuji
• Tanoue Takeshi

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title